“This multicenter real-world study suggests that first-line tislelizumab combined with platinum-etoposide chemotherapy provides encouraging efficacy with an acceptable safety profile in patients with ...

T-cell lymphomas represent a heterogeneous and often aggressive group of hematologic malignancies for which the optimal consolidation strategy, autologous or allogeneic hematopoietic stem cell ...

The second clinical scenario considers a 72-year-old patient with multiple myeloma who is triple-class exposed and has experienced disease progression after a BCMA-directed T-cell-engaging therapy.

Ottensmeier C, Delord JP, Lalanne A, et al. A viral-based individualized neoantigen vaccine as adjuvant treatment in resected head and neck squamous cell carcinoma: a randomized phase I trial. Nat ...

The Community Oncology Alliance is urging CMS and Congress to address Medicare Part B drug negotiation policies that threaten independent cancer practices and patient access.

Forsyth P, Law V, Grogan P, et al. Intrathecal dendritic cell therapy in a first-in-human trial for breast cancer ...

"Patients [with cancer] and physicians would rather have a fixed-duration treatment, if possible," said Julie M. Vose, MD, MBA, at SOHO 2026. Posters highlighted sex-based differences in aggressive ...

Poster sessions at WCLC 2026 detail how surgery, nursing, and pathology can contribute to the multidisciplinary care of ...

Jasmine Zain, MD, described how pre-existing CHIP mutations should inform pre-infusion risk counseling and treatment ...

The FDA cleared the Triton 1 robotic endoscopy system for diagnostic and therapeutic procedures such as colorectal cancer ...

A positive CHMP opinion supports the perioperative use of pembrolizumab plus enfortumab vedotin in resectable MIBC regardless of cisplatin eligibility. The European Medicines Agency’s (EMA’s) ...

"Patients [with cancer] and physicians would rather have a fixed-duration treatment, if possible," said Julie M. Vose, MD, MBA, at SOHO 2026.